Dr. Cia Berger Medical

26/08/2026

A very good article on rational statin therapy by Peter Wurst.

Approximately 200 million people worldwide take the same class of drug every day.

A drug whose prescription has increased more than 1,000% since it was first introduced in 1987. That is now the most prescribed medication in most developed countries. That generates around 15 billion dollars in annual global revenue even after most major versions became generic. That is recommended by the world's most influential cardiovascular guidelines not only for people with established heart disease but for tens of millions of people who have never had a cardiovascular event.

The mainstream medical establishment describes it as one of the most important public health interventions in history — saving hundreds of thousands of lives annually from heart attack and stroke.

A significant minority of physicians, cardiologists, and researchers describe it as one of the most overprescribed medications in the history of medicine — genuinely beneficial for a well-defined high-risk group while being prescribed to tens of millions of people who derive minimal benefit and are exposed to real side effects that the medical establishment has, in their view, systematically underestimated.

That drug is the statin.

Atorvastatin (Lipitor). Rosuvastatin (Crestor). Simvastatin (Zocor). Pravastatin (Pravachol).

This is not a guide about whether statins are good or bad. That framing is too simple for a drug with genuine evidence in some contexts and genuine evidence of overprescription in others.

This is a guide about what the evidence actually shows, where commercial interests have distorted it, what the side effects actually are, and what every person taking statins or considering them deserves to understand.

Because the decision to take a statin — or to continue taking one — should be made with full information. And full information is not what most people have been given. 🌿

🔬 𝐖𝐇𝐀𝐓 𝐒𝐓𝐀𝐓𝐈𝐍𝐒 𝐀𝐂𝐓𝐔𝐀𝐋𝐋𝐘 𝐃𝐎 — 𝐈𝐍 𝐏𝐋𝐀𝐈𝐍 𝐋𝐀𝐍𝐆𝐔𝐀𝐆𝐄

Statins work by blocking a specific enzyme in the liver that produces cholesterol. That enzyme — HMG-CoA reductase — is the key step in the body's cholesterol manufacturing process. When statins block it, the liver produces less cholesterol of its own.

In response to the reduced internal supply, the liver increases the number of receptors on its surface that pull LDL cholesterol out of the bloodstream. More receptors mean more LDL cleared from the blood — which is why statins lower your LDL cholesterol reading on a blood test. Depending on the statin and the dose, LDL drops by roughly 30 to 60 percent.

𝐓𝐡𝐞 𝐩𝐫𝐨𝐛𝐥𝐞𝐦 𝐰𝐢𝐭𝐡 𝐛𝐥𝐨𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐢𝐬 𝐩𝐚𝐭𝐡𝐰𝐚𝐲:

The cholesterol manufacturing process in the liver does not only produce cholesterol. It produces a range of other biologically essential molecules that are also reduced when statins block the pathway. This is one of the most clinically important and most underappreciated aspects of statin pharmacology.

The most significant of these:

𝐂𝐨𝐐𝟏𝟎 — 𝐭𝐡𝐞 𝐞𝐧𝐞𝐫𝐠𝐲 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐞:

CoQ10 (also called ubiquinol in its active form) is the molecule your mitochondria — the energy-producing engines inside every cell — use to generate ATP, the fuel that powers every biological process in your body. It is also the primary antioxidant protecting the inner mitochondrial membrane from damage.

Statins reduce CoQ10 production by 40 to 50 percent. This is not a minor side note — it is the most mechanistically compelling explanation for statins' most common side effect: muscle pain and weakness. Muscle cells depleted of CoQ10 cannot produce energy efficiently. They tire more easily, they hurt, and in severe cases they can break down.

Other molecules reduced alongside cholesterol include compounds required for cell signaling, protein processing, and vitamin K2 metabolism — all of which have downstream biological consequences that extend beyond the cardiovascular system.

𝐒𝐭𝐚𝐭𝐢𝐧𝐬 𝐝𝐨 𝐦𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝐥𝐨𝐰𝐞𝐫 𝐜𝐡𝐨𝐥𝐞𝐬𝐭𝐞𝐫𝐨𝐥:

Beyond LDL reduction, statins have biological effects on the cardiovascular system that operate independently of cholesterol:

→ They reduce inflammation — lowering CRP and other inflammatory markers through effects on inflammatory signaling molecules; some researchers believe this is actually more important than the cholesterol-lowering effect for cardiovascular benefit
→ They improve the function of the blood vessel lining — enhancing nitric oxide production and reducing vascular inflammation
→ They stabilize atherosclerotic plaques — making existing plaques in arteries less likely to rupture; and it is plaque rupture, not plaque size, that causes most heart attacks

These additional effects make it genuinely difficult to separate how much of statins' cardiovascular benefit comes from lowering LDL and how much comes from these other actions. This matters enormously for understanding who actually benefits and why.

📜 𝐓𝐇𝐄 𝐇𝐈𝐒𝐓𝐎𝐑𝐘 — 𝐅𝐑𝐎𝐌 𝐅𝐔𝐍𝐆𝐔𝐒 𝐓𝐎 𝐓𝐇𝐄 𝐌𝐎𝐒𝐓 𝐏𝐑𝐄𝐒𝐂𝐑𝐈𝐁𝐄𝐃 𝐃𝐑𝐔𝐆 𝐈𝐍 𝐇𝐈𝐒𝐓𝐎𝐑𝐘

The discovery of statins is one of the more genuinely remarkable episodes in the history of drug development.

In 1971, a Japanese biochemist named Akira Endo began searching through more than 6,000 samples of microbial fermentation broths — reasoning that fungi living in competition with bacteria might produce natural compounds that inhibited cholesterol-like molecules in bacterial cell walls. In 1973, he found what he was looking for in a blue-green mold found on rice. He had discovered the first statin.

Merck's research team, aware of Endo's work, isolated a related compound in 1978 from a different mold. This became lovastatin — the first commercially available statin, FDA-approved in 1987. Endo, who did the foundational work, received no royalties and relatively little initial credit — a situation partially corrected decades later when he received the Lasker Award, one of medicine's highest honors, in 2008.

One detail worth noting: Akira Endo himself — the man who discovered statins — has been outspoken in his view that they are overprescribed. The founder of the field believes the primary benefit is in people with established cardiovascular disease, not in the broad primary prevention population to whom they are now routinely prescribed.

𝐓𝐡𝐞 𝐩𝐢𝐯𝐨𝐭𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬:

The clinical case for statins was built through a series of large randomized controlled trials primarily in the 1990s and 2000s:

The 4S trial (1994) — 4,444 patients with established coronary heart disease randomized to simvastatin or placebo for over five years. Simvastatin significantly reduced both total deaths and major cardiovascular events. The absolute reduction in all-cause mortality was approximately 3.3 percentage points — meaning you would need to treat roughly 30 people for five years to prevent one death. In a high-risk population with established heart disease, this is genuinely clinically significant. This remains the most compelling statin evidence.

WOSCOPS (1995) — 6,595 men with elevated LDL but no history of heart attack, randomized to pravastatin or placebo for five years. Pravastatin significantly reduced heart attacks and cardiovascular death. The absolute risk reduction was approximately 2.4 percentage points — meaning roughly 42 people would need to be treated for five years to prevent one cardiovascular event. Importantly, this was a high-risk male population with very elevated cholesterol. Extrapolating to lower-risk populations or to women requires caution.

JUPITER (2008) — 17,802 people with normal LDL but elevated CRP (an inflammatory marker), randomized to rosuvastatin or placebo. The trial was stopped early after less than two years because interim results showed significant benefit. This trial is among the most contested in statin medicine:

→ It was funded by AstraZeneca, manufacturer of rosuvastatin; multiple investigators had financial relationships with the company
→ Stopping trials early typically exaggerates apparent benefit — the most dramatic results appear early, and longer follow-up usually shows smaller effects
→ The absolute risk reduction was very small — approximately 1.2% fewer cardiovascular events over less than two years; around 95 people would need to be treated for that period to prevent one event in one person
→ New-onset diabetes increased significantly in the statin group — roughly one additional diabetes case for every 167 people treated

⚖️ 𝐓𝐇𝐄 𝐌𝐎𝐒𝐓 𝐈𝐌𝐏𝐎𝐑𝐓𝐀𝐍𝐓 𝐓𝐇𝐈𝐍𝐆 𝐘𝐎𝐔 𝐍𝐄𝐄𝐃 𝐓𝐎 𝐔𝐍𝐃𝐄𝐑𝐒𝐓𝐀𝐍𝐃 — 𝐑𝐄𝐋𝐀𝐓𝐈𝐕𝐄 𝐕𝐒 𝐀𝐁𝐒𝐎𝐋𝐔𝐓𝐄 𝐑𝐈𝐒𝐊

This is the most practically important statistical concept for evaluating statin prescribing — and the one most consistently omitted from the conversations doctors have with patients about starting a statin.

𝐓𝐡𝐞 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞:

Relative risk reduction sounds impressive and is the number used in most statin marketing and most doctor conversations about statin benefits.

Absolute risk reduction is what a drug actually does for a specific person — the real difference in how many events occur between treated and untreated groups.

𝐀𝐧 𝐞𝐱𝐚𝐦𝐩𝐥𝐞 𝐭𝐡𝐚𝐭 𝐦𝐚𝐤𝐞𝐬 𝐭𝐡𝐞 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐜𝐥𝐞𝐚𝐫:

Imagine 100 people take a placebo. Four of them have a heart attack. Now imagine 100 people take a statin. Three of them have a heart attack.

The relative risk reduction is 25% — because three is 25% lower than four. That sounds meaningful.

The absolute risk reduction is 1% — because 4% minus 3% = 1%.

The number needed to treat (NNT) — how many people must take the drug for the given period to prevent one heart attack in one person — is 100.

Whether a 1% absolute risk reduction over five years justifies daily medication with its associated side effects is a question people can only meaningfully engage with if they know the absolute figure. Most people taking statins have been given only the relative risk reduction — which sounds much more impressive than the absolute number.

𝐖𝐡𝐚𝐭 𝐭𝐡𝐞 𝐍𝐔𝐌𝐁𝐄𝐑𝐒 𝐥𝐨𝐨𝐤 𝐥𝐢𝐤𝐞 𝐢𝐧 𝐫𝐞𝐚𝐥𝐢𝐭𝐲:

For people who have already had a heart attack or have established cardiovascular disease (secondary prevention):

→ Roughly 25 to 40 people need to be treated for five years to prevent one major cardiovascular event — a genuinely meaningful benefit in a high-risk population
→ Roughly 30 to 50 people need to be treated to prevent one death over five years
→ This is where the strongest case for statins exists, and where the evidence is clearest

For people with risk factors but no cardiovascular disease (primary prevention):

→ Roughly 60 to 100 people need to be treated for five years to prevent one non-fatal heart attack
→ In lower-risk primary prevention populations, you may need to treat 200 to 500 people for five years to prevent one cardiovascular death
→ Many primary prevention trials do not show significant reduction in all-cause deaths — only in cardiovascular events — suggesting any cardiovascular benefit may be partly offset by other effects including increased diabetes risk

𝐓𝐡𝐞 𝐜𝐨𝐦𝐦𝐮𝐧𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐟𝐚𝐢𝐥𝐮𝐫𝐞:

A study published in the European Heart Journal found that when statin risks and benefits were presented in absolute terms (absolute risk reduction and NNT), around 50% of patients said they would choose not to take a statin. When the same information was presented in relative terms (relative risk reduction), the majority said they would take it. The framing of the information changes the decision made by a large proportion of patients.

This is not necessarily deliberate deception by individual doctors — it reflects how statin information has been presented in guidelines and medical culture for decades. But it produces a systematic failure of informed consent that prominent researchers have described as one of the most consequential communication failures in modern medicine.

💊 𝐓𝐇𝐄 𝐒𝐈𝐃𝐄 𝐄𝐅𝐅𝐄𝐂𝐓𝐒 — 𝐖𝐇𝐀𝐓 𝐓𝐇𝐄 𝐄𝐕𝐈𝐃𝐄𝐍𝐂𝐄 𝐀𝐂𝐓𝐔𝐀𝐋𝐋𝐘 𝐒𝐇𝐎𝐖𝐒

🔴 Muscle pain and weakness — the most common and most disputed

The official position: muscle symptoms affect roughly 5 to 10% of statin users in real-world practice. Serious muscle disease is rare. A widely cited 2020 study argued that most statin-related muscle symptoms are "nocebo" effect — meaning people experience symptoms because they expect to, not because of the drug's actual pharmacological action.

The counter-evidence that complicates this picture:

→ The 2020 nocebo study had significant limitations: only 60 patients completed the full protocol, and many people with genuine statin-related muscle symptoms had already stopped statins before being enrolled — systematically excluding the most affected people
→ The rate of muscle symptoms reported in real-world settings (electronic health records, patient-reported outcomes) is consistently 15 to 25% — substantially higher than in clinical trials, which are known to exclude people most likely to experience side effects before randomization
→ Muscle biopsies from statin users with muscle complaints consistently show structural abnormalities in mitochondria, impaired energy production, and depleted CoQ10 — objective physical findings that cannot be attributed to expectation effects
→ The CoQ10 mechanism is biologically compelling: muscles depleted of CoQ10 cannot produce energy normally; they are genuinely impaired, not simply expecting to be

The practical response: CoQ10 (ubiquinol form, 200 to 400mg daily) is the most direct nutritional intervention for statin-associated muscle symptoms. Clinical trials of CoQ10 for statin myalgia have produced mixed results, but the biological rationale is sound, the supplement carries no significant risk, and an empirical trial is reasonable for anyone experiencing muscle symptoms on a statin.

🔴 Diabetes — the most clearly established non-muscle risk

This is the statin side effect that even mainstream clinical literature acknowledges clearly.

Statins increase the risk of developing type 2 diabetes by approximately 10 to 15% in relative terms. In absolute terms, this translates to roughly one new diabetes case per 100 to 250 people treated per year, depending on baseline risk and statin potency. Higher-potency statins — rosuvastatin and high-dose atorvastatin — produce higher diabetes risk than lower-potency statins.

Why it happens: statins impair insulin secretion from pancreatic cells (through their effects on molecules the cells need to function), reduce the ability of muscle cells to absorb glucose after meals (through CoQ10-related mitochondrial dysfunction), and may impair liver glucose metabolism. Multiple mechanisms suggest this is a genuine pharmacological effect, not a coincidence.

The clinical irony: statins are frequently prescribed to people with metabolic syndrome and insulin resistance — precisely the population most vulnerable to statin-induced diabetes. A drug that increases diabetes risk being prescribed to people who are already pre-diabetic requires a very careful and explicit benefit-risk conversation that most people are not having.

🔴 Cognitive effects — the most contested side effect

Memory problems and cognitive difficulties are among the most commonly reported complaints in statin user communities. The FDA added a warning about memory loss and confusion to statin labels in 2012.

The official clinical consensus: statins do not cause significant cognitive impairment and may actually reduce dementia risk. Cognitive complaints are attributed to the nocebo effect or to normal aging.

The concerns that are not adequately addressed by this reassurance:

→ The brain contains approximately 25% of all the cholesterol in the body. Cholesterol is essential for forming new synaptic connections, producing myelin (the insulating sheath around nerve fibers), and releasing neurotransmitters. The biological plausibility of cognitive effects from aggressive cholesterol lowering is real
→ Lipophilic statins — the fat-soluble ones including simvastatin, atorvastatin, and lovastatin — cross the blood-brain barrier and directly reduce cholesterol synthesis in the brain. Hydrophilic statins (pravastatin, rosuvastatin) do not. Case reports of cognitive side effects are considerably more common with fat-soluble statins, which is consistent with a central nervous system mechanism

The practical implication: if someone starting a statin notices memory problems, word-finding difficulties, or mental fogginess, these should not be automatically dismissed. A supervised trial period off the statin with monitoring of cognitive function is a legitimate clinical approach that most prescribers do not proactively offer.

🔴 Increased bleeding stroke risk

Multiple large trials and meta-analyses show that statins are associated with a small but statistically significant increased risk of hemorrhagic stroke — bleeding in the brain — even as they reduce ischemic stroke (stroke from a blocked vessel). For most people the reduction in ischemic stroke risk substantially outweighs this risk. But for people with specific hemorrhagic stroke risk factors — high blood pressure, significant alcohol use, or prior hemorrhagic stroke — this deserves explicit consideration.

🔴 Liver effects

Mild elevations in liver enzymes occur in approximately 1 to 3% of statin users. Serious liver injury from statins is rare. The FDA removed the requirement for routine liver monitoring from statin labels in 2012, though many specialists continue to recommend periodic checks — particularly in patients with pre-existing liver disease including the fatty liver that is extremely common in the metabolic syndrome population frequently being prescribed statins.

🔴 Tendon problems and other effects

Beyond muscles, statins have been associated with tendinopathy (tendon inflammation and damage), peripheral neuropathy (nerve damage producing numbness or pain, particularly in long-term users), and cataracts (a 2012 study found a 27% increased risk). These are less commonly discussed but documented in the literature.

𝐖𝐡𝐲 𝐬𝐢𝐝𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐬 𝐚𝐫𝐞 𝐮𝐧𝐝𝐞𝐫𝐫𝐞𝐩𝐨𝐫𝐭𝐞𝐝 𝐢𝐧 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬:

Clinical trials are a poor instrument for detecting statin side effects for several structural reasons:

→ Most large statin trials include a placebo run-in phase where people who experience early adverse effects are removed before the trial even begins — systematically selecting a population less prone to side effects
→ Trials exclude many people with conditions that increase side effect risk — pre-existing liver or kidney disease, muscle conditions, thyroid problems, and patients on multiple interacting medications; these excluded people may have substantially higher side effect rates
→ Side effects that develop gradually over years may not appear in trials lasting 4 to 5 years
→ Adverse effects are typically patient-reported rather than systematically sought through functional assessments

The result is that the side effect rates published in clinical trial literature are consistently lower than those observed in real-world clinical practice.

🔴 𝐓𝐇𝐄 𝐂𝐎𝐌𝐌𝐄𝐑𝐂𝐈𝐀𝐋 𝐈𝐍𝐓𝐄𝐑𝐄𝐒𝐓𝐒 — 𝐇𝐎𝐖 𝐓𝐇𝐄 𝐄𝐕𝐈𝐃𝐄𝐍𝐂𝐄 𝐖𝐀𝐒 𝐒𝐇𝐀𝐏𝐄𝐃

The statin story cannot be told honestly without acknowledging the extraordinary commercial interests that have shaped the evidence base, the guidelines, and the prescribing culture.

The majority of researchers who conducted the landmark statin trials, who sit on the guideline committees that determine prescribing recommendations, and who provide expert commentary that shapes clinical practice have financial relationships with statin manufacturers — research funding, speaking fees, consultancy payments, and advisory board memberships.

A 2011 analysis found that the majority of authors of the American Heart Association and American College of Cardiology cholesterol guidelines had financial relationships with pharmaceutical companies.

𝐓𝐡𝐞 𝐝𝐚𝐭𝐚 𝐚𝐜𝐜𝐞𝐬𝐬 𝐩𝐫𝐨𝐛𝐥𝐞𝐦:

The Cholesterol Treatment Trialists (CTT) collaboration — the group that produces the most influential summary analyses of statin trial data, based at Oxford and funded significantly by statin manufacturers — has declined to make its individual patient data available for independent researchers to verify. This refusal is unusual in medical research. The most influential evidence summary in the statin field rests on data that cannot be independently validated. Peter Gøtzsche, co-founder of the Cochrane Collaboration and one of medicine's most prominent experts on research methodology, has stated that this refusal alone is sufficient reason to treat the official statin evidence claims with significant skepticism.

𝐓𝐡𝐞 𝐠𝐮𝐢𝐝𝐞𝐥𝐢𝐧𝐞 𝐞𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 𝐩𝐫𝐨𝐛𝐥𝐞𝐦:

In 2013, the American College of Cardiology and American Heart Association released new guidelines replacing specific LDL targets with a risk-based approach. The new guidelines recommended statins for anyone with a 10-year cardiovascular risk of 7.5% or greater — a threshold that statistical modeling suggested would bring approximately 13 million additional Americans into the statin-eligible population who would not have qualified under previous guidelines.

Within days of publication, two prominent biostatisticians published a paper in The Lancet showing that the risk calculator used in the new guidelines significantly overestimated cardiovascular risk in validation populations — in some cases predicting twice as many events as actually occurred. If the risk calculator overstates risk, many people classified as eligible for statins may not actually be at sufficient risk to benefit. The controversy was never satisfactorily resolved. The guidelines remained in place.

🔴 𝐓𝐇𝐄 𝐋𝐃𝐋 𝐃𝐄𝐁𝐀𝐓𝐄 — 𝐈𝐒 𝐇𝐈𝐆𝐇 𝐋𝐃𝐋 𝐀𝐂𝐓𝐔𝐀𝐋𝐋𝐘 𝐓𝐇𝐄 𝐏𝐑𝐎𝐁𝐋𝐄𝐌?

One of the most fundamental challenges to the standard statin rationale is the growing questioning of LDL cholesterol's role as the primary driver of heart disease.

𝐓𝐡𝐞 𝐜𝐚𝐬𝐞 𝐟𝐨𝐫 𝐋𝐃𝐋 𝐚𝐬 𝐚 𝐜𝐚𝐮𝐬𝐚𝐥 𝐟𝐚𝐜𝐭𝐨𝐫:

People born with the genetic condition familial hypercholesterolaemia — which dramatically elevates LDL from birth — develop premature atherosclerosis and heart disease at very high rates. Genetic variants that naturally lower LDL are associated with lower cardiovascular disease risk in population studies. Drugs that lower LDL through a completely different mechanism (PCSK9 inhibitors) also reduce cardiovascular events. The evidence that very high LDL is causally relevant to cardiovascular disease is real.

𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬:

→ LDL and elderly mortality: a landmark 2016 BMJ Open paper reviewing studies of over 68,000 elderly people found that those with the highest LDL had the lowest mortality. This finding is profoundly inconsistent with the simple LDL hypothesis and suggests the relationship between LDL and cardiovascular risk changes with age in ways the standard prescribing model does not adequately account for

→ LDL particles are not all the same: LDL cholesterol is not a single entity — it consists of particles of very different sizes with very different atherogenic properties. Small, dense LDL particles oxidize easily, pe*****te artery walls more readily, and are associated with dramatically higher cardiovascular risk. Large, buoyant LDL particles are relatively benign. Standard LDL-C — the test that statins target — measures the total cholesterol content of all LDL regardless of particle type; it does not distinguish between the dangerous and benign varieties

→ ApoB is a better marker: ApoB — the protein present on the surface of every potentially atherogenic lipoprotein particle — counts the number of harmful particles directly rather than their cholesterol content. Two people with identical LDL-C can have very different ApoB and very different cardiovascular risk. ApoB is increasingly recognized as the more meaningful cardiovascular risk marker

→ Oxidation matters as much as quantity: LDL contributes to atherosclerosis primarily when it becomes oxidized and is engulfed by immune cells inside artery walls. The susceptibility of LDL to oxidation depends on antioxidant status and inflammatory environment — not just on the quantity of LDL present. Addressing the oxidative and inflammatory environment may be as or more important than reducing LDL quantity

→ Inflammation may be the primary driver: the JUPITER trial found elevated CRP (an inflammation marker) to be a better predictor of events than elevated LDL in the study population. A significant number of cardiovascular researchers now argue that inflammation, not LDL, is the primary driver of atherosclerosis — with LDL as a substrate and marker rather than the root cause

🔴 𝐖𝐇𝐎 𝐌𝐎𝐒𝐓 𝐂𝐋𝐄𝐀𝐑𝐋𝐘 𝐁𝐄𝐍𝐄𝐅𝐈𝐓𝐒 — 𝐀𝐍𝐃 𝐖𝐇𝐎 𝐌𝐎𝐒𝐓 𝐂𝐋𝐄𝐀𝐑𝐋𝐘 𝐃𝐎𝐄𝐒 𝐍𝐎𝐓

𝐓𝐡𝐞 𝐜𝐥𝐞𝐚𝐫𝐞𝐬𝐭 𝐜𝐚𝐬𝐞𝐬 𝐟𝐨𝐫 𝐬𝐭𝐚𝐭𝐢𝐧𝐬:

→ People who have had a heart attack or acute coronary syndrome: the strongest and most consistent evidence; secondary prevention produces meaningful absolute risk reduction in both cardiovascular events and death; the benefit-risk balance is most clearly favorable here
→ People with established atherosclerotic cardiovascular disease — prior stroke, peripheral arterial disease, confirmed coronary artery disease: similar rationale and evidence strength
→ People with familial hypercholesterolaemia — the genetic condition producing dramatically elevated LDL from birth; risk of untreated disease is very high and the evidence for benefit is strong
→ People at genuinely very high calculated 10-year cardiovascular risk (above 20%): absolute risk is high enough that even modest relative risk reductions produce meaningful absolute benefit

𝐓𝐡𝐞 𝐥𝐞𝐚𝐬𝐭 𝐜𝐥𝐞𝐚𝐫 𝐜𝐚𝐬𝐞𝐬:

→ Primary prevention in lower-risk people (10-year cardiovascular risk below 10%): absolute risk reduction is very small; the NNT is large; side effect risk is the same as in higher-risk populations; the benefit-risk balance is much less favorable; many independent cardiologists argue that statins should not be routinely prescribed in this group

→ Women in primary prevention: the evidence for statin benefit in primary prevention is substantially weaker in women than men; many landmark primary prevention trials enrolled primarily or exclusively male participants; the Cochrane review of primary prevention statins found insufficient evidence for benefit in women specifically; extrapolating male-population results to women is not well-supported

→ People over 75 in primary prevention: the LDL-mortality relationship appears to reverse in elderly populations; evidence for primary prevention statin benefit specifically in this age group is very limited; side effect risk (particularly muscle effects and cognitive effects) may be greater in older people

→ People with metabolic syndrome or insulin resistance without established cardiovascular disease: the modest primary prevention benefit combined with the specific diabetes risk statins carry in this population — the exact group most vulnerable to statin-induced diabetes — requires very careful and explicit individual consideration

🛠️ 𝐈𝐅 𝐘𝐎𝐔 𝐀𝐑𝐄 𝐓𝐀𝐊𝐈𝐍𝐆 𝐒𝐓𝐀𝐓𝐈𝐍𝐒 — 𝐓𝐇𝐄 𝐏𝐑𝐀𝐂𝐓𝐈𝐂𝐀𝐋 𝐆𝐔𝐈𝐃𝐄

If you are currently taking a statin — and particularly if you have concerns about it — the most important thing is to engage with this information in conversation with your prescribing physician rather than making unilateral changes.

Statins should not be stopped abruptly without medical guidance — particularly in people with established cardiovascular disease, where abrupt discontinuation carries real cardiovascular risk.

𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬 𝐞𝐯𝐞𝐫𝐲 𝐬𝐭𝐚𝐭𝐢𝐧 𝐮𝐬𝐞𝐫 𝐝𝐞𝐬𝐞𝐫𝐯𝐞𝐬 𝐭𝐨 𝐚𝐬𝐤 𝐭𝐡𝐞𝐢𝐫 𝐝𝐨𝐜𝐭𝐨𝐫:

→ What is my absolute risk reduction from this statin — not the relative percentage, but the actual reduction in my personal risk of a cardiovascular event over the next ten years?
→ What is my NNT — how many people with my risk profile need to take this drug for ten years to prevent one cardiovascular event in one person?
→ Am I taking this for secondary prevention (I have established cardiovascular disease) or primary prevention (I have risk factors but no disease)? The evidence is very different for these two situations
→ Has my cardiovascular risk been recalculated recently? Someone who has lost weight, improved blood pressure, quit smoking, or improved metabolic health may have substantially lower risk than when their statin was first prescribed
→ Has my ApoB been measured rather than just my LDL-C? ApoB gives a more clinically meaningful picture of atherogenic particle burden
→ What is my CoQ10 status? If experiencing muscle symptoms, this is a reasonable and direct clinical question
→ Am I on the lowest effective dose? Side effects are dose-dependent — the lowest dose that achieves the intended effect is preferable

𝐌𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠 𝐨𝐧 𝐬𝐭𝐚𝐭𝐢𝐧𝐬:

→ CoQ10 — consider baseline measurement and periodic reassessment; ubiquinol 200 to 400mg daily for anyone experiencing muscle symptoms or significant fatigue; reasonable for all statin users given the documented depletion
→ Blood glucose and HbA1c — statins increase diabetes risk; periodic monitoring of glucose status is appropriate; addressing insulin resistance through lifestyle reduces this risk
→ Liver enzymes — periodic monitoring is reasonable, particularly at higher doses or in anyone with pre-existing liver concerns
→ Muscle symptoms — any new muscle pain, weakness, or fatigue should be reported; creatine kinase (CK) measurement assesses degree of muscle damage; significant CK elevation warrants medical review and potentially statin discontinuation
→ Cognitive function — any new memory problems, word-finding difficulties, or mental fogginess should be taken seriously and not automatically attributed to aging or expectation

𝐓𝐡𝐞 𝐥𝐢𝐟𝐞𝐬𝐭𝐲𝐥𝐞 𝐟𝐨𝐮𝐧𝐝𝐚𝐭𝐢𝐨𝐧 — 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐜𝐨𝐧𝐭𝐞𝐱𝐭:

Statins reduce cardiovascular risk; they do not eliminate the biological processes that drive cardiovascular disease. The insulin resistance, chronic inflammation, gut dysbiosis, endothelial dysfunction, and oxidative stress that drive atherosclerosis are more fundamentally addressed by dietary improvement, exercise, sleep, stress management, and targeted nutritional support than by cholesterol lowering alone.

The PREDIMED trial demonstrated that a Mediterranean diet rich in olive oil and nuts reduced cardiovascular events by 30% in high-risk patients — an effect size comparable to or greater than that of statins in primary prevention, without side effects. Dietary change is cardiovascular medicine.

The most important nutritional supports alongside statin use:

→ CoQ10 (ubiquinol) 200 to 400mg daily — replenishing what statins deplete; supporting mitochondrial energy production in muscle and heart
→ Vitamin K2 (MK-7 form) — directs calcium away from arterial walls and toward bones; particularly relevant for statin users as the mevalonate pathway inhibition may affect K2 metabolism; one of the most evidence-supported supplements for preventing arterial calcification
→ Omega-3 EPA plus DHA (2 to 3g daily) — the most evidence-supported cardiovascular risk reduction supplement; reduces triglycerides, reduces platelet aggregation, reduces arrhythmia risk, and reduces the inflammatory environment in which LDL oxidizes and atherosclerosis develops
→ Addressing insulin resistance — the insulin resistance of metabolic syndrome produces the small dense LDL particle pattern and elevated ApoB that represents the most atherogenic lipid profile; improving insulin sensitivity produces more favorable changes in the atherogenic lipid pattern than cholesterol lowering alone

💚 𝐓𝐇𝐄 𝐃𝐄𝐄𝐏𝐄𝐑 𝐓𝐑𝐔𝐓𝐇

Statins are not the villains of a simple story about pharmaceutical industry corruption of medicine.

They are genuinely effective medications for a specific and well-defined population: people with established cardiovascular disease, prior heart attacks, very high cardiovascular risk, or genetic hypercholesterolaemia. In these people, the absolute risk reduction is meaningful, the NNT is reasonably small, and the cardiovascular benefit likely outweighs the side effects for most individuals.

The problem is not the drug. It is the systematic expansion of prescribing from the population where the evidence is genuinely strong into a primary prevention population where the absolute risk reduction is tiny, the NNT is large, the side effects are real and substantially underreported, and the evidence base has been significantly shaped by commercial interests with billions of dollars at stake in the prescribing decision.

The researchers who have published the most rigorous critiques of the statin evidence base — Peter Gøtzsche, John Abramson, Rita Redberg, Barbara Roberts, Michel de Lorgeril, Uffe Ravnskov — are not fringe figures. They are senior academics and clinicians at major institutions who have applied to statin evidence the same methodological standards that evidence-based medicine is supposed to apply to all evidence. What they have found is a body of literature that is more equivocal, more limited, and more commercially compromised than the mainstream narrative acknowledges.

The 200 million people taking statins globally deserve access to this full picture.

They deserve to know their absolute risk reduction rather than just their relative risk reduction.

They deserve to know the NNT that applies to their specific risk profile — how many people like them need to take this drug for how long to benefit one of them.

They deserve to know about the diabetes risk, the muscle symptoms and the CoQ10 mechanism that explains them, the cognitive effect concerns, and the data access problems that prevent independent verification of the most important evidence claims.

They deserve the conversation that time-pressured clinical appointments rarely make possible — an honest engagement with what this drug does and does not do for them specifically, with their specific risk profile, their specific side effect experience, and their specific preferences about how to reduce their cardiovascular risk.

Some people will weigh that full information and decide — reasonably, on the evidence — that the statin is worth taking.

Some people will weigh that same information and decide — equally reasonably, on the evidence — that the lifestyle changes and nutritional interventions that address the underlying biology of cardiovascular disease are a more compelling primary strategy for them.

Both decisions can be rational. Both deserve to be made with full information.

What is not acceptable — and what has characterized too much of the statin prescribing conversation for too long — is a decision made on the basis of a relative risk reduction number that sounds more impressive than it is, in the absence of the absolute risk data that would allow genuine informed consent.

Every person deciding whether to take a statin deserves the truth. 💊🌿

📌 This guide is for educational purposes only and is not medical advice. Do not stop or change statin medication without consulting your prescribing doctor — particularly if you have established cardiovascular disease. The information here is intended to support informed conversations with healthcare practitioners, not to replace medical judgment.

Download free resources about holistic health and natural healing